Previous close | 206.06 |
Open | 208.81 |
Bid | 203.29 x 800 |
Ask | 214.32 x 800 |
Day's range | 206.58 - 209.62 |
52-week range | 180.93 - 348.67 |
Volume | |
Avg. volume | 358,580 |
Market cap | 8.083B |
Beta (5Y monthly) | 0.53 |
PE ratio (TTM) | 90.28 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 15, 2024.
Penumbra, Inc. (NYSE: PEN), the world's largest thrombectomy company, announced the U.S. Food and Drug Administration (FDA) clearance and launch of Lightning Flash™ 2.0, the next generation computer assisted vacuum thrombectomy (CAVT) system to remove venous thrombus and treat pulmonary emboli (PE). Lightning Flash 2.0 features advanced Lightning Flash algorithms, designed for increased speed and sensitivity to thrombus and blood flow. These new advancements combined with Penumbra's novel cathet
Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2024 after market close on Tuesday, May 7, 2024 at 4:30 PM Eastern Time. A press release with first quarter 2024 financial results will be issued after market close that day.